Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 2
2005 1
2006 1
2008 3
2009 4
2011 1
2012 3
2013 4
2014 6
2015 10
2016 11
2017 17
2018 19
2019 11
2020 9
2021 17
2022 17
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: hajarizadeh b. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Hepatitis C elimination in Australia: progress and challenges.
Martinello M, Hajarizadeh B, Dore GJ. Martinello M, et al. Among authors: hajarizadeh b. Med J Aust. 2020 May;212(8):362-363. doi: 10.5694/mja2.50584. Epub 2020 Apr 19. Med J Aust. 2020. PMID: 32306399 No abstract available.
Epidemiology and natural history of HCV infection.
Hajarizadeh B, Grebely J, Dore GJ. Hajarizadeh B, et al. Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62. doi: 10.1038/nrgastro.2013.107. Epub 2013 Jul 2. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23817321 Review.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Among authors: hajarizadeh b. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, Willing A, Kairouz A, Cunningham EB, Hajarizadeh B, Leung J, Tran LT, Price O, Peacock A, Vickerman P, Farrell M, Dore GJ, Hickman M, Grebely J. Degenhardt L, et al. Among authors: hajarizadeh b. Lancet Glob Health. 2023 May;11(5):e659-e672. doi: 10.1016/S2214-109X(23)00057-8. Epub 2023 Mar 27. Lancet Glob Health. 2023. PMID: 36996857 Free article.
146 results